CPG Lymph Dx - SUQCRL Flashcards
International Society of Lymphology (ISL) Classification of Lymphedema Severity
- At Risk = insult to LS, wo/sx or signs of impaired lymphatic transport non-ISL
- Stage 0 = sub clinical state = impaired lymphatic transport, no peripheral swelling; Sx and subtle skin changes may be present
- Stage I = early Lymph = early onset visible swelling that subsides w/elevation; pitting may/may not be present
- Stage II = Moderate Lymph = pitting; consistent volume change; fibrosis may/may not be present [progressive fibrosis]
- Stage III = Late Lymph = nonpitting; skin changes; very fibrotic
Clinical Examination and Patient-Reported Symptom Assessments:
Clinical Examination for All Patients at risk for SUQL
- Palpation: for fibrosis, pitting, and overall tissue quality - may be clinically helpful for staging; however, it has not been investigated for diagnostic purposes.
- H/N: HN-ELAF can be used w/CM for Dx purposes
Clinical Examination and Patient-Reported Symptom Assessments:
Patient-Reported Sx Assessments for All Patients at risk for SUQL
- Self-reported symptoms: of swelling, heaviness, and numbness should be investigated for early diagnosis —> should signal clinician to use other SUQL Measures
- Questionnaires to Consider to Assist in Dx: the Norman Questionnaire; or the Morbidity Screening Tool
Categories and subcategories for practice recommendations were written for the following:
-All patients at risk for SUQL
-Secondary upper-extremity lymphedema
—>At risk, early
—>Moderate/established
—>Late
-Lymphedema primarily in the hand
-Trunk/breast lymphedema
-Head and neck lymphedema
Bioimpedance analysis should be used to detect _____________ and diagnose _____ and _______ _______ in patients at risk for ________
Bioimpedance analysis should be used to detect lymphatic transport impairments and diagnose subclinical and early-stage lymphedema in patients at risk for breast cancer–related lymphedema
L-Dex Score: Dx Criterion if No Preop Baseline Available
L-Dex score of more than 7.1 should be used as a diagnostic criterion for breast cancer–related lymphedema when no preoperative assessment is available.
L-Dex Score: Dx Criterion if Preop Baseline Available
score of more than 10 above preoperative baseline measures should be used as a diagnostic criterion.
BIA in moderate- to late-stage breast cancer–related lymphedema ___ be used as a Dx tool, however, clinicians must be aware of the potential for ________ ECF even with ____ tissue volume.
In moderate- to late-stage breast cancer–related lymphedema, as fibrosis and tissue changes occur, BIA may be used as a diagnostic tool; however, clinicians must be aware of the potential for decreasing extracellular fluid even with increased tissue volume.
BIA may not capture _______ _____ such as fibrosis or adipose infiltration that are seen in _____-______ lymphedema.
BIA may not capture tissue changes such as fibrosis or adipose infiltration that are seen in later-stage lymphedema.
Volume assessment tools for clinicians
Perimeter; water displacement; CM; 3-D imaging; more?
Some have established diagnostic criterion
Are clinical volume assessment tools interchangeable?
No.
They are not equivalent and thus not interchangeable.
Clinicians should use the same method for all assessments of an individual.
Circumferential Measurements for UQSL
- UE - Dx tool
- Hand - assessment tool
- H/N - assessment tool
CM should be used to Dx UE Lymphedema stage ___ or greater
CM should be used to Dx UE Lymphedema stage I or greater
—> with or without hand involvement!
UE CM Volume Ratio indicative of Lymphedema
A volume ratio of 1.04 may be indicative of upper-extremity lymphedema
UE CM Calculated volume differential between sides:
1) > or = ____ will help rule in lymphedema BUT
2) values < ____ cannot be used to rule out.
Calculated volume differential between sides (≥200 mL) will help rule in lymphedema, but values below 200 mL cannot be used to rule out.